Breaking News Instant updates and real-time market news.

2020-12-18 08:12:02 PFBC Preferred Bank $46.12 / -0.7 (-1.50%) 08:12 12/18/20 12/18 08:12 12/18/20 08:12	B. Riley upgrades Preferred Bank ahead of 'significant' earnings improvement B. Riley Securities analyst Steve Moss upgraded Preferred Bank to Buy from Neutral with a price target of $64, up from $45. The analyst expects "significant" earnings improvement in 2021 due to lower credit costs and modest net interest income growth. Further, he finds the stock attractively valued at 8.7 times his revised 2021 estimate. Preferred's credit costs should abate as its loan loss reserves are strong, Moss tells investors in a research note.
PFBC Preferred Bank $46.12 / -0.7 (-1.50%) 12/18/20 B. Riley Securities Preferred Bank upgraded to Buy from Neutral at B. Riley Securities 12/04/20 B. Riley Securities Preferred Bank price target raised to $45 from $40 at B. Riley Securities 06/04/20 Piper Sandler Preferred Bank assumed with an Overweight at Piper Sandler 01/07/20 Raymond James Preferred Bank downgraded to Market Perform from Outperform at Raymond James

2020-12-18 08:12:02

PFBC

Preferred Bank

$46.12 / -0.7 (-1.50%)

08:12

12/18/20

12/18

08:12

12/18/20

08:12

B. Riley upgrades Preferred Bank ahead of 'significant' earnings improvement

B. Riley Securities analyst Steve Moss upgraded Preferred Bank to Buy from Neutral with a price target of $64, up from $45. The analyst expects "significant" earnings improvement in 2021 due to lower credit costs and modest net interest income growth. Further, he finds the stock attractively valued at 8.7 times his revised 2021 estimate. Preferred's credit costs should abate as its loan loss reserves are strong, Moss tells investors in a research note.

PFBC Preferred Bank

$46.12 / -0.7 (-1.50%)

12/18/20 B. Riley Securities: Preferred Bank upgraded to Buy from Neutral at B. Riley Securities

12/04/20 B. Riley Securities: Preferred Bank price target raised to $45 from $40 at B. Riley Securities

06/04/20 Piper Sandler: Preferred Bank assumed with an Overweight at Piper Sandler

01/07/20 Raymond James: Preferred Bank downgraded to Market Perform from Outperform at Raymond James

TODAY'S FREE FLY STORIES

Downgrade	DBV Technologies downgraded to Sell from Hold at Societe Generale » 05:25 01/22/21 01/22 05:25 01/22/21 05:25 DBVT DBV Technologies $6.51 / +0.02 (+0.31%) Societe Generale analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly DBVT DBV Technologies $6.51 / +0.02 (+0.31%) 01/15/21 DBV Technologies gets feedback from FDA regarding Viaskin Peanut regulatory path 01/07/21 DBV Technologies restructuring plan to result in reduction of over 200 jobs 11/24/20 DBV Technologies CSO Hugh Sampson to step down from role 11/02/20 DBV Technologies receives validation for Viaskin Peanut MAA by EMA DBVT DBV Technologies $6.51 / +0.02 (+0.31%) 01/18/21 Goldman Sachs DBV Technologies price target raised to $7 from $4 at Goldman Sachs 01/15/21 Citi DBV Technologies price target raised to $8 from $4 at Citi 01/15/21 H.C. Wainwright DBV now has 'clear developmental path,' says H.C. Wainwright 11/02/20 Societe Generale DBV Technologies upgraded to Hold on improved visibility at Societe Generale DBVT DBV Technologies $6.51 / +0.02 (+0.31%) 07/31/20 DBV Technologies reports first half EPS EUR (1.62) vs. EUR (2.43) last year 30 Jan DBVT DBV Technologies $6.51 / +0.02 (+0.31%) 01/15/21 Fly Intel: Wall Street's top stories for Friday 01/15/21 Fly Intel: Wall Street's top stories at midday 01/15/21 Fly Intel: Pre-market Movers 11/02/20 Fly Intel: Pre-market Movers
Initiation	Sage Group initiated with a Buy at Peel Hunt » 05:24 01/22/21 01/22 05:24 01/22/21 05:24 SGPYY Sage Group $0.00 / + (+0.00%) Peel Hunt analyst Damindu… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research SGPYY Sage Group $0.00 / + (+0.00%) 01/14/21 Sage Group says AgeMark moves to Sage Intacct solution 12/16/20 Sage announces Sage Partner Cloud Program in the U.S., Canada SGPYY Sage Group $0.00 / + (+0.00%) 01/11/21 Canaccord Sage Group price target lowered to 680 GBp from 700 GBp at Canaccord 12/10/20 Morgan Stanley Sage Group upgraded to Equal Weight from Underweight at Morgan Stanley 11/25/20 JPMorgan Sage Group price target lowered to 560 GBp from 600 GBp at JPMorgan 11/24/20 UBS Sage Group price target lowered to 550 GBp from 610 GBp at UBS
Downgrade	Gerresheimer downgraded to Hold from Buy at Pareto » 05:22 01/22/21 01/22 05:22 01/22/21 05:22 GRRMF Gerresheimer $0.00 / + (+0.00%) Pareto analyst Zafer… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research GRRMF Gerresheimer $0.00 / + (+0.00%) 07/29/20 Berenberg Gerresheimer price target raised to EUR 115 from EUR 75 at Berenberg
Downgrade	Siltronic downgraded to Neutral from Buy at Oddo BHF » 05:21 01/22/21 01/22 05:21 01/22/21 05:21 SSLLF Siltronic $0.00 / + (+0.00%) Oddo BHF analyst Stephane… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research SSLLF Siltronic $0.00 / + (+0.00%) 01/12/21 Deutsche Bank Siltronic price target raised to EUR 150 from EUR 135 at Deutsche Bank 12/11/20 Jefferies Siltronic downgraded to Hold from Buy at Jefferies 12/04/20 UBS Siltronic price target raised to EUR 125 from EUR 85 at UBS 12/02/20 Berenberg Siltronic price target raised to EUR 125 from EUR 85 at Berenberg
Upgrade	Carl Zeiss Meditec upgraded to Hold from Sell at DZ Bank » 05:20 01/22/21 01/22 05:20 01/22/21 05:20 CZMWY Carl Zeiss Meditec $0.00 / + (+0.00%) DZ Bank analyst Sven… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research CZMWY Carl Zeiss Meditec $0.00 / + (+0.00%) 10/07/20 Microsoft, Zeiss announce multi-year strategic partnership CZMWY Carl Zeiss Meditec $0.00 / + (+0.00%) 01/20/21 Berenberg Carl Zeiss Meditec price target raised to EUR 127 from EUR 87 at Berenberg 01/20/21 Deutsche Bank Carl Zeiss Meditec price target raised to EUR 140 from EUR 120 at Deutsche Bank 11/02/20 Deutsche Bank Carl Zeiss Meditec price target raised to EUR 120 from EUR 110 at Deutsche Bank 10/23/20 UBS Carl Zeiss Meditec downgraded to Neutral from Buy at UBS

Upgrade	Ericsson upgraded to Buy from Hold at Nordea » 05:19 01/22/21 01/22 05:19 01/22/21 05:19 ERIC Ericsson $11.77 / -0.08 (-0.68%) Nordea analyst Sami… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals Events Options ERIC Ericsson $11.77 / -0.08 (-0.68%) 01/13/21 T-Mobile announces five-year agreements with Ericsson, Nokia 12/17/20 Nokia appoints Nishant Batra as chief strategy, technology officer 12/17/20 Veoneer CTO Nishant Batra to leave for Nokia, Giuseppe Rosso named acting CTO 11/10/20 Ericsson announces new long-term financial targets at Capital Markets Day ERIC Ericsson $11.77 / -0.08 (-0.68%) 01/14/21 Barclays Ericsson price target lowered to SEK 120 from SEK 125 at Barclays 11/20/20 UBS Ericsson price target raised to SEK 102 from SEK 86 at UBS 11/12/20 Societe Generale Ericsson upgraded to Buy from Hold at Societe Generale 10/22/20 Barclays Ericsson price target raised to SEK 125 from SEK 110 at Barclays ERIC Ericsson $11.77 / -0.08 (-0.68%) 10/21/20 Ericsson reports Q3 EPS SEK 1.61 vs. (SEK 1.89) last year ERIC Ericsson $11.77 / -0.08 (-0.68%) 01/08/21 Samsung files ITC case to block Ericsson 5G imports, Bloomberg reports 10/20/20 Swedish regulators ban Huawei, ZTE from upcoming 5G networks, Reuters reports 02/11/21 Technology & Internet Virtual Conference 01/29/21 Ericsson - ERIC ERIC Ericsson $11.77 / -0.08 (-0.68%) 01/05/21 Unusually active option classes on open January 5th 11/10/20 Ericsson put volume heavy and directionally bearish 10/14/20 Ericsson call volume above normal and directionally bullish 10/13/20 Unusually active option classes on open October 13th
Downgrade	Syrah Resources downgraded to Neutral from Outperform at Credit Suisse » 05:18 01/22/21 01/22 05:18 01/22/21 05:18 SYAAF Syrah Resources $0.00 / + (+0.00%) Credit Suisse analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Downgrade	Air France-KLM downgraded to Reduce from Hold at Kepler Cheuvreux » 05:18 01/22/21 01/22 05:18 01/22/21 05:18 AFLYY Air France-KLM $0.00 / + (+0.00%) Kepler Cheuvreux analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals AFLYY Air France-KLM $0.00 / + (+0.00%) 12/04/20 KLM, Delta to offer COVID-19 tested flights from Atlanta to Amsterdam AFLYY Air France-KLM $0.00 / + (+0.00%) 01/20/21 Barclays Air France-KLM price target raised to EUR 5.10 from EUR 2.70 at Barclays 12/04/20 Deutsche Bank Air France-KLM price target raised to EUR 3.50 from EUR 2.10 at Deutsche Bank 12/01/20 UBS Air France-KLM price target raised to EUR 4.45 from EUR 3.35 at UBS 11/12/20 Kepler Cheuvreux Air France-KLM upgraded to Hold from Reduce at Kepler Cheuvreux AFLYY Air France-KLM $0.00 / + (+0.00%) 07/30/20 Air France-KLM sees 'significantly negative' EBITDA in second half 07/30/20 Air France-KLM reports Q2 revenue EUR 1.18B vs. EUR 7.02B last year AFLYY Air France-KLM $0.00 / + (+0.00%) 12/22/20 Germany extends U.K. travel ban to January 6, Sky News reports 09/24/20 KLM steps up labor talks aimed to securing wage cuts, Bloomberg reports 09/01/20 Air France-KLM plans to raise funds by May of next year, Bloomberg reports
Downgrade	Alstom downgraded to Hold from Buy at Kepler Cheuvreux » 05:17 01/22/21 01/22 05:17 01/22/21 05:17 ALSMY Alstom $0.00 / + (+0.00%) Kepler Cheuvreux analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals ALSMY Alstom $0.00 / + (+0.00%) 12/01/20 Bombardier, Alstom confirm receipt of all necessary approvals for transaction 09/16/20 Bombardier announces SPA for sale of transportation business to Alstom 07/31/20 European Commission clears Alstom's acquisition of Bombardier Transportation 07/28/20 Linde to begin construction on hydrogen refueling station for trains in Germany ALSMY Alstom $0.00 / + (+0.00%) 01/20/21 Jefferies Alstom upgraded to Buy from Hold at Jefferies 01/12/21 Deutsche Bank Alstom price target raised to EUR 47 from EUR 45 at Deutsche Bank 12/11/20 Credit Suisse Alstom upgraded to Outperform from Neutral at Credit Suisse 12/08/20 Morgan Stanley Alstom price target raised to EUR 55 from EUR 51 at Morgan Stanley ALSMY Alstom $0.00 / + (+0.00%) 07/27/20 EU set to approve with conditions Alstom, Bombardier deal, Reuters reports
Downgrade	IAG downgraded to Reduce from Hold at Kepler Cheuvreux » 05:17 01/22/21 01/22 05:17 01/22/21 05:17 ICAGY IAG $0.00 / + (+0.00%) Kepler Cheuvreux analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals ICAGY IAG $0.00 / + (+0.00%) 07/24/20 IAG 'evaluating the merits of a rights issue' of up to EUR 2.75B ICAGY IAG $0.00 / + (+0.00%) 01/20/21 Barclays IAG price target raised to 175 GBp from 120 GBp at Barclays 12/31/20 Fly Intel: Top five analyst calls 12/31/20 Citi IAG upgraded to Buy from Neutral at Citi 12/04/20 Deutsche Bank IAG price target raised to 220 GBp from 175 GBp at Deutsche Bank ICAGY IAG $0.00 / + (+0.00%) 12/07/20 IAG dismisses Ryanair comments on British Airways holding, Reuters says 11/05/20 British Airways to reduce flight schedule in November, Reuters reports

Upgrade	Adient upgraded to Neutral from Underweight at JPMorgan » 05:16 01/22/21 01/22 05:16 01/22/21 05:16 ADNT Adient $35.26 / -0.71 (-1.97%) JPMorgan analyst Ryan… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ADNT Adient $35.26 / -0.71 (-1.97%) 08/14/20 Greenlight Capital exits Altice, takes stake in Atlas Air ADNT Adient $35.26 / -0.71 (-1.97%) 01/20/21 Deutsche Bank Adient price target raised to $43 from $37 at Deutsche Bank 12/17/20 Barclays Adient price target raised to $45 from $37 at Barclays 12/16/20 KeyBanc Adient price target raised to $43 from $36 at KeyBanc 12/02/20 Deutsche Bank Adient price target raised to $37 from $27 at Deutsche Bank ADNT Adient $35.26 / -0.71 (-1.97%) 11/30/20 Adient sees FY21 revenue $14.6B-$15B, consensus $14.47B 11/30/20 Adient reports Q4 adj. EPS $1.15, consensus 71c 08/06/20 Adient sees Q4 revenue $3.3B-$3.5B, consensus $3.31B 08/06/20 Adient reports Q3 adj. EPS ($2.78), consensus ($2.08) 02/05/21 Adient - ADNT
Downgrade	Gentherm downgraded to Underweight from Neutral at JPMorgan » 05:16 01/22/21 01/22 05:16 01/22/21 05:16 THRM Gentherm $70.38 / -0.6 (-0.85%) JPMorgan analyst Ryan… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings THRM Gentherm $70.38 / -0.6 (-0.85%) 01/11/21 Gentherm appoints Betsy Meter to board of directors 01/04/21 Gentherm appoints Steve Fletcher as SVP, GM of Medical 10/29/20 Gentherm to delay Q3 conference call 10/15/20 Gentherm launches ASTOPAD Patient Warming System THRM Gentherm $70.38 / -0.6 (-0.85%) 12/23/20 Barrington Gentherm double downgraded to Underperform at Barrington following rally 12/23/20 Barrington Gentherm downgraded to Underperform from Outperform at Barrington 10/30/20 Roth Capital Gentherm price target raised to $53 from $44 at Roth Capital 10/22/20 JPMorgan Gentherm price target raised to $48 from $43 at JPMorgan THRM Gentherm $70.38 / -0.6 (-0.85%) 10/29/20 Gentherm sees Q4 product revenues $240M-$260M, consensus $228.41M 10/29/20 Gentherm reports Q3 adjusted EPS 91c, consensus 49c 08/04/20 Gentherm not providing update to FY20 guidance 08/04/20 Gentherm sees Q3 product revenues $210M-$240M, consensus $212.53M
Upgrade	Lear upgraded to Overweight from Neutral at JPMorgan » 05:16 01/22/21 01/22 05:16 01/22/21 05:16 LEA Lear $168.15 / +0.79 (+0.47%) JPMorgan analyst Ryan… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events LEA Lear $168.15 / +0.79 (+0.47%) 01/14/21 Cerence, Xevo collaborate for to deliver Cerence Pay payment capabilities 01/11/21 Lear partners with GrubHub to deliver ordering capabilities in FCA vehicles 11/18/20 Lear reinstates quarterly cash dividend at 25c per share 11/16/20 Paulson & Co. buys Lear, cuts Tiffany in Q3 LEA Lear $168.15 / +0.79 (+0.47%) 01/20/21 Deutsche Bank Lear price target raised to $165 from $150 at Deutsche Bank 01/08/21 Guggenheim Lear downgraded to Neutral from Buy at Guggenheim 12/17/20 Barclays Lear upgraded to Overweight from Equal Weight at Barclays 12/16/20 Argus Lear upgraded to Buy at Argus on high expected demand following COVID LEA Lear $168.15 / +0.79 (+0.47%) 10/30/20 Lear reinstates FY20 revenue view $16.35B-$16.65B, consensus $16.45B 10/30/20 Lear reports Q3 adj. EPS $3.73, consensus $3.14 08/04/20 Lear not providing FY20 guidance due to COVID-19 08/04/20 Lear reports Q2 adj. EPS ($4.14), consensus ($4.67) LEA Lear $168.15 / +0.79 (+0.47%) 12/19/20 Charged: Deutsche sees multiple EV winners, says buy Xpev 02/04/21 Lear - LEA
Downgrade	Visteon downgraded to Underweight from Neutral at JPMorgan » 05:16 01/22/21 01/22 05:16 01/22/21 05:16 VC Visteon $142.17 / +0.6 (+0.42%) JPMorgan analyst Ryan… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings VC Visteon $142.17 / +0.6 (+0.42%) 12/07/20 Cognex names Visteon CEO Lawande to board of directors VC Visteon $142.17 / +0.6 (+0.42%) 01/20/21 Deutsche Bank Visteon price target raised to $166 from $105 at Deutsche Bank 12/17/20 Barclays Visteon price target raised to $150 from $101 at Barclays 11/19/20 Baird Visteon price target raised to $130 from $105 at Baird 11/03/20 Goldman Sachs Visteon upgraded to Neutral from Sell at Goldman Sachs VC Visteon $142.17 / +0.6 (+0.42%) 10/29/20 Visteon reports Q3 adjusted EPS $1.36, consensus 50c 07/30/20 Visteon reports Q2 EPS ($1.62), consensus ($2.12)
Downgrade	Aptiv downgraded to Neutral from Overweight at JPMorgan » 05:15 01/22/21 01/22 05:15 01/22/21 05:15 APTV Aptiv $143.95 / -1.16 (-0.80%) JPMorgan analyst Ryan… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research Earnings Syndicate On The Fly Events APTV Aptiv $143.95 / -1.16 (-0.80%) 01/20/21 Deutsche Bank Aptiv price target raised to $160 from $120 at Deutsche Bank 12/22/20 Citi Citi 'very skeptical' of Apple car, says Tesla most direct competitor 12/17/20 Barclays Aptiv price target raised to $145 from $112 at Barclays 12/16/20 Argus Aptiv initiated with a Buy at Argus on 'attractive valuation' APTV Aptiv $143.95 / -1.16 (-0.80%) 10/29/20 Aptiv sees FY20 adj. EPS $1.65-$1.80, consensus $1.28 10/29/20 Aptiv reports Q3 ex-items EPS $1.13, consensus 76c 07/30/20 Aptiv not reporting Q3, FY20 guidance at this time 07/30/20 Aptiv reports Q2 EPS ex-items ($1.10), consensus ($1.38) 10 Jun APTV Aptiv $143.95 / -1.16 (-0.80%) 12/26/20 Charged: Apple's potential EV entry seen as 'Tesla bear case' 12/22/20 Apple rises as Wall Street digests report of self-driving car plans 09/18/20 Fly Intel: Wall Street's top stories at midday 02/11/21 Technology & Internet Virtual Conference 02/03/21 Aptiv - APTV

Downgrade	TGS-NOPEC downgraded to Sell from Neutral at UBS » 05:15 01/22/21 01/22 05:15 01/22/21 05:15 TGSGY TGS-NOPEC $0.00 / + (+0.00%) UBS analyst Amy Wong… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research TGSGY TGS-NOPEC $0.00 / + (+0.00%) 10/09/20 UBS TGS-NOPEC price target lowered to NOK 135 from NOK 145 at UBS 10/09/20 DNB Markets TGS-NOPEC downgraded to Sell from Hold at DNB Markets 10/09/20 Danske Bank TGS-NOPEC downgraded to Hold from Buy at Danske Bank 08/19/20 Fearnley TGS-NOPEC downgraded to Sell from Buy at Fearnley
Downgrade	Bunzl downgraded to Equal Weight from Overweight at Barclays » 05:14 01/22/21 01/22 05:14 01/22/21 05:14 BZLFF Bunzl $0.00 / + (+0.00%) Barclays analyst James… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Downgrade	Vifor Pharma downgraded to Sell from Neutral at UBS » 05:13 01/22/21 01/22 05:13 01/22/21 05:13 GNHAF Vifor Pharma / + UBS analyst Laura… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research GNHAF Vifor Pharma / + 11/09/20 Vifor Pharma, Angion sign licensing agreement for ANG-3777 commercialization 10/20/20 Vifor Pharma, Cara Therapeutics enter license agreement for Korsuva Injection GNHAF Vifor Pharma / + 05:13 Today UBS Vifor Pharma downgraded to Sell from Neutral at UBS 01/04/21 JPMorgan Vifor Pharma downgraded to Underweight from Neutral at JPMorgan 10/22/20 Credit Suisse Vifor Pharma price target lowered to CHF 149 from CHF 152 at Credit Suisse 10/21/20 JPMorgan Vifor Pharma price target lowered to CHF 130 from CHF 175 at JPMorgan
Downgrade	Vifor Pharma downgraded to Sell from Neutral at UBS » 05:13 01/22/21 01/22 05:13 01/22/21 05:13 GNHAF Vifor Pharma $0.00 / + (+0.00%) UBS analyst Laura… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research GNHAF Vifor Pharma $0.00 / + (+0.00%) 11/09/20 Vifor Pharma, Angion sign licensing agreement for ANG-3777 commercialization 10/20/20 Vifor Pharma, Cara Therapeutics enter license agreement for Korsuva Injection GNHAF Vifor Pharma $0.00 / + (+0.00%) 01/04/21 JPMorgan Vifor Pharma downgraded to Underweight from Neutral at JPMorgan 10/22/20 Credit Suisse Vifor Pharma price target lowered to CHF 149 from CHF 152 at Credit Suisse 10/21/20 JPMorgan Vifor Pharma price target lowered to CHF 130 from CHF 175 at JPMorgan 10/21/20 UBS Vifor Pharma price target lowered to CHF 129 from CHF 142 at UBS
Earnings	Chemung Financial reports Q4 EPS $1.11, consensus $1.02 » 05:11 01/22/21 01/22 05:11 01/22/21 05:11 CHMG Chemung Financial $33.76 / -1.16 (-3.32%) Reports Q4 net… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings CHMG Chemung Financial $33.76 / -1.16 (-3.32%) 01/08/21 Chemung Financial announces 250,000 share repurchase program CHMG Chemung Financial $33.76 / -1.16 (-3.32%) 10/22/20 DA Davidson Chemung Financial downgraded to Neutral from Buy at DA Davidson 03/09/20 DA Davidson Chemung Financial upgraded to Buy from Neutral at DA Davidson CHMG Chemung Financial $33.76 / -1.16 (-3.32%) 10/19/20 Chemung Financial reports Q3 EPS $1.19, consensus 67c

Downgrade	Sage Therapeutics downgraded to Market Perform from Outperform at BMO Capital » 05:08 01/22/21 01/22 05:08 01/22/21 05:08 SAGE Sage Therapeutics $92.45 / +1.19 (+1.30%) BMO Capital analyst Gary… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events SAGE Sage Therapeutics $92.45 / +1.19 (+1.30%) 01/07/21 Sage Therapeutics plans to advance SAGE-319, SAGE-421 to preclinical studies 12/16/20 Sage Therapeutics names Barry Greene as CEO 11/27/20 Sage Therapeutics trading resumes 11/27/20 Sage Therapeutics to resume trading at 8 am ET SAGE Sage Therapeutics $92.45 / +1.19 (+1.30%) 01/19/21 Wedbush Sage Therapeutics price target raised to $98 from $83 at Wedbush 01/04/21 Sage Therapeutics downgraded to Sector Perform at RBC Capital on valuation 01/04/21 Guggenheim Sage Therapeutics upgraded to Buy from Neutral at Guggenheim 01/04/21 RBC Capital Sage Therapeutics downgraded to Sector Perform from Outperform at RBC Capital SAGE Sage Therapeutics $92.45 / +1.19 (+1.30%) 11/05/20 Sage Therapeutics reports Q3 EPS ($2.03), consensus ($2.39) 08/10/20 Sage Therapeutics reports Q2 EPS ($2.63), consensus ($2.66) SAGE Sage Therapeutics $92.45 / +1.19 (+1.30%) 12/04/20 Delta, United, Boeing downgrades among today's top calls on Wall Street 11/27/20 Fly Intel: Wall Street's top stories for Friday 11/27/20 Fly Intel: Pre-market Movers 03/01/21 41st Annual Healthcare Virtual Conference
Downgrade	Regis downgraded to Hold from Buy at Jefferies » 05:07 01/22/21 01/22 05:07 01/22/21 05:07 RGS Regis $9.25 / +0.195 (+2.15%) Jefferies analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly RGS Regis $9.25 / +0.195 (+2.15%) 12/02/20 Regis announces brand-centric reorganization 11/29/20 Fly Intel: Top five weekend stock stories 11/02/20 Regis falls -9.0% 11/02/20 Regis says about 80% of company's salon portfolio franchised at Q1-end RGS Regis $9.25 / +0.195 (+2.15%) 10/30/20 B. Riley Securities Regis price target raised to $160 from $155 at B. Riley Securities 10/22/20 Loop Capital Regis downgraded to Hold from Buy at Loop Capital 10/22/20 Loop Capital Regis downgraded to Hold from Buy at Loop Capital 06/19/20 Loop Capital Regis price target lowered to $15 from $21 at Loop Capital RGS Regis $9.25 / +0.195 (+2.15%) 11/02/20 Regis reports Q1 adjusted EPS (78c), consensus (12c) 08/31/20 Regis reports Q4 adjusted EPS ($1.01), consensus (66c) RGS Regis $9.25 / +0.195 (+2.15%) 11/28/20 Supercuts owner Regis stock a post-COVID play, Barron's says RGS Regis $9.25 / +0.195 (+2.15%) 11/02/20 Fly Intel: Pre-market Movers 08/31/20 Fly Intel: Wall Street's top stories for Monday 08/31/20 Fly Intel: Wall Street's top stories at midday 08/31/20 Fly Intel: Pre-market Movers
Upgrade	Seagate upgraded to Buy from Hold at Summit Insights » 05:07 01/22/21 01/22 05:07 01/22/21 05:07 STX Seagate $63.00 / +1.57 (+2.56%) Summit Insights analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options STX Seagate $63.00 / +1.57 (+2.56%) 01/21/21 Seagate says 2020 'a very challenging year' 01/19/21 Nidec files patent infringement suit against Seagate 12/28/20 Seagate appoints Prat Bhatt to Board of Directors 12/16/20 Intel announces next generation of memory and storage products STX Seagate $63.00 / +1.57 (+2.56%) 05:04 Today Benchmark Seagate price target raised to $70 from $60 at Benchmark 01/21/21 Barclays Seagate price target raised to $60 from $41 at Barclays 01/20/21 Wedbush Seagate price target raised to $56 from $47 at Wedbush 01/19/21 Northland Seagate price target raised to $72 from $65 at Northland STX Seagate $63.00 / +1.57 (+2.56%) 01/21/21 Seagate sees Q3 adjusted EPS $1.30, plus/minus 15c, consensus $1.26 01/21/21 Seagate reports Q2 adjusted EPS $1.29, consensus $1.13 10/22/20 Seagate sees Q2 adjusted EPS $1.10, plus/minus 15c, consensus $1.08 10/22/20 Seagate reports Q1 adjusted EPS 93c, consensus 88c STX Seagate $63.00 / +1.57 (+2.56%) 01/21/21 Fly Intel: After-Hours Movers 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street 10/23/20 Fly Intel: Wall Street's top stories for Friday 10/23/20 Fly Intel: Wall Street's top stories at midday STX Seagate $63.00 / +1.57 (+2.56%) 01/21/21 Seagate options imply 7.9% move in share price post-earnings 12/28/20 Largest borrow rate increases among liquid names 12/21/20 Seagate call volume above normal and directionally bullish 12/01/20 Seagate call volume above normal and directionally bullish
Downgrade	CSX downgraded to Hold from Buy at Stifel » 05:06 01/22/21 01/22 05:06 01/22/21 05:06 CSX CSX $91.61 / -1.6101 (-1.73%) Stifel analyst David Ross… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options CSX CSX $91.61 / -1.6101 (-1.73%) 01/20/21 North American rail traffic rose 8.6% in the week ended January 16 01/14/21 North American rail traffic rose 3% in the week ended January 9 01/07/21 North American rail traffic rose 1.3% in the week ended January 2 12/31/20 North American rail traffic rose 7% in week ended December 26 CSX CSX $91.61 / -1.6101 (-1.73%) 01/20/21 Susquehanna Railroad recovery expected to continue in 2021, says Susquehanna 01/11/21 Citi CSX price target raised to $105 from $87 at Citi 12/10/20 Morgan Stanley Morgan Stanley downgrades CSX to Underweight with bar raised too high 12/10/20 Morgan Stanley CSX downgraded to Underweight from Equal Weight at Morgan Stanley CSX CSX $91.61 / -1.6101 (-1.73%) 01/21/21 CSX reports Q4 EPS 99c, consensus $1.00 01/21/21 Notable companies reporting after market close 10/21/20 CSX reports Q3 EPS 96c, consensus 92c 10/21/20 Notable companies reporting after market close CSX CSX $91.61 / -1.6101 (-1.73%) 01/21/21 Fly Intel: After-Hours Movers 10/21/20 Fly Intel: After-Hours Movers CSX CSX $91.61 / -1.6101 (-1.73%) 01/21/21 CSX options imply 4.6% move in share price post-earnings 10/22/20 Early notable gainers among liquid option names on October 22nd 09/15/20 CSX call volume above normal and directionally bullish 09/04/20 CSX put volume heavy and directionally bearish
Upgrade	PacWest Bancorp upgraded to Outperform from Market Perform at Keefe Bruyette » 05:05 01/22/21 01/22 05:05 01/22/21 05:05 PACW PacWest Bancorp $30.33 / +0.345 (+1.15%) Keefe Bruyette analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research Earnings PACW PacWest Bancorp $30.33 / +0.345 (+1.15%) 01/12/21 Fly Intel: Top five analyst initiations 01/12/21 Piper Sandler PacWest Bancorp assumed with an Overweight at Piper Sandler 01/04/21 Wells Fargo PacWest Bancorp upgraded to Overweight from Equal Weight at Wells Fargo 12/15/20 Truist Truist raises price targets on select regional banks PACW PacWest Bancorp $30.33 / +0.345 (+1.15%) 01/20/21 PacWest Bancorp reports Q4 EPS 99v, consensus 67v 10/14/20 PacWest Bancorp reports Q3 EPS 38c, consensus 63c

Events

Earnings calls, analyst events, roadshows and more

TBK
Today at 08:00

Triumph Bancorp - TBK Conference Calls
PPG
Today at 08:00

PPG - PPG Conference Calls
EDU
Today at 08:00

New Oriental Education - EDU Conference Calls
HBAN
Today at 08:30

Huntington Bancshares - HBAN Conference Calls
SLB
Today at 08:30

Schlumberger - SLB Conference Calls
BMTC
Today at 08:30

Bryn Mawr Bank - BMTC Conference Calls
KSU
Today at 08:45

Kansas City Southern - KSU Conference Calls
ALLY
Today at 09:00

Ally Financial - ALLY Conference Calls
TRST
Today at 09:00

Trustco Bank - TRST Conference Calls
DNMR
Today at 09:00

Danimer Scientific - DNMR Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	BDGE X BDGE Bridge Bancorp Block Trade Managers: Morgan Stanley Priced at: $25.50 700K Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TCRR X TCRR TCR2 Therapeutics Secondary Managers: Goldman Sachs, Jefferies, Piper Sandler & BMO Capital Priced at: $30.50 4.59M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACRS X ACRS Aclaris Therapeutics Spot Secondary Managers: Cantor Fitzgerald & William Blair, H.C. Wainwright Priced at: $17.50 5.484M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACRX X ACRX AcelRx Spot Secondary Managers: Cantor Fitzgerald Priced at: $1.90 14.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BLRX X BLRX BioLineRx Spot Secondary Managers: H.C. Wainwright Priced at: $2.40 12.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNGO X BNGO Bionano Genomics Spot Secondary Managers: Oppenheimer, BTIG, Ladenburg, Maxim Priced at: $6.00 33.333M Shares DSS X DSS Document Security Spot Secondary Managers: Aegis Priced at: $3.60 6.67M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FULC X FULC Fulcrum Therapeutics Spot Secondary Managers: SVB Leerink, Piper Sandler & Credit Suisse Priced at: $11.00 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LAC X LAC Lithium Americas Spot Secondary Managers: Canaccord, Deutsche Bank, Evercore ISI, Stifel Priced at: $22.00 15.9M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PERI X PERI Perion Network Spot Secondary Managers: Oppenheimer, Stifel, Roth Capital, LAKE Priced at: $11.50 4.99M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYRS X SYRS Syros Pharmaceuticals Spot Secondary Managers: Cowen & Piper Sandler Priced at: $14.00 5.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	DFH X DFH Dream Finders Homes IPO Managers: BofA, RBC Capital & BTIG, Builder Advisor, Zelman, TCB Capital, Wedbush Priced at: $13.00 9.6M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MYTE X MYTE Mytheresa IPO Managers: Morgan Stanley & JPMorgan, Credit Suisse, UBS, Jefferies, Cowen Priced at: $26.00 15.647M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ATHA X ATHA Athira Pharma Secondary Managers: Goldman Sachs, Jefferies, Stifel & JMP Securities Priced at: $22.50 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CDNA X CDNA CareDx Secondary Managers: Goldman Sachs & Jefferies, Raymond James, BTIG, Craig-Hallum, H.C. Wainwright Priced at: $91.00 1.923M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CMRX X CMRX Chimerix Secondary Managers: Jefferies & Cowen, H.C. Wainwright, JonesTrading Priced at: $8.50 11.765M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CTMX X CTMX CytomX Therapeutics Secondary Managers: JPMorgan, Cowen & Piper Sandler Priced at: $7.00 14.286M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DYN X DYN Dyne Therapeutics Secondary Managers: JPMorgan, Jefferies, Piper Sandler & Stifel Priced at: $28.00 6M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EDIT X EDIT Editas Medicine Secondary Managers: JPMorgan & Morgan Stanley, Cowen, Credit Suisse Priced at: $66.00 3.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MRUS X MRUS Merus Secondary Managers: Jefferies & SVB Leerink Priced at: $24.75 4.85M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CYRX X CYRX Cryoport Spot Secondary Managers: Morgan Stanley, Jefferies, SVB Leerink & UBS Priced at: $66.00 3.788M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INO X INO Inovio Spot Secondary Managers: BofA, Jefferies & Cantor Fitzgerald, Oppenheimer Priced at: $8.50 2.655M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ONCS X ONCS OncoSec Spot Secondary Managers: BTIG Priced at: $5.45 7.71M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ORC X ORC Orchid Island Capital Spot Secondary Managers: JPMorgan Priced at: $5.30 7.6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	RLX X RLX RLX Technology IPO Managers: Citi, China Renaissance Priced at: $12.00 116.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AZEK X AZEK Azek Secondary Managers: Barclays, BofA, Goldman Sachs & Jefferies Priced at: $40.00 20M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CRSR X CRSR Corsair Gaming Secondary Managers: Goldman Sachs, Barclays, Credit Suisse, Macquarie, Baird, Cowen & Stifel, Wedbush, Academy Securities Priced at: $35.00 7.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NVTA X NVTA Invitae Secondary Managers: JPMorgan, Morgan Stanley, Cowen & SVB Leerink Priced at: $51.50 7.77M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PASG X PASG Passage Bio Secondary Managers: JPMorgan, Goldman Sachs & Cowen, Wedbush, Chardan Priced at: $22.00 7M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SI X SI Silvergate Capital Secondary Managers: Goldman Sachs, Keefe Bruyette & Canaccord, Compass Point, Craig-Hallum Priced at: $63.00 3.968M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACB X ACB Aurora Cannabis Spot Secondary Managers: BMO Capital, ATB Capital Markets Priced at: $10.45 12M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	VRAY X VRAY ViewRay Block Trade Managers: Morgan Stanley $4.75-4.95 11.5M Shares PAX X PAX Patria IPO Managers: JPMorgan, BofA & Credit Suisse, Goldman Sachs, Bradesco BBI, BTG Pactual, ITAU, Keefe Bruyette, Santander, XP $14.00-16.00 26.65M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DCBO X DCBO Docebo Secondary Managers: Morgan Stanley, Goldman Sachs & Canaccord $70.51 3.65M Shares GSL X GSL Global Ship Lease Spot Secondary Managers: Jefferies & B. Riley Securities $13.00-14.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PGEN X PGEN Precigen Spot Secondary Managers: Wells Fargo & Stifel, JMP Securities, H.C. Wainwright $7.50-8.00 SENS X SENS Senseonics Spot Secondary Managers: H.C. Wainwright $2.42 25.974M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

View All Syndicate Announcements »

B. Riley upgrades Preferred Bank ahead of 'significant' earnings improvement

TODAY'S FREE FLY STORIES

Get Full Fly Access